ArticleScientific reports2025
HearteXplain: explainable prediction of acute heart failure and identification of hematologic biomarkers using EBMs and Morris sensitivity analysis.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hematological biomarkers have emerged as powerful tools in diagnosing Acute Heart Failure (AHF). This study introduces a novel diagnostic framework that integrates Explainable Artificial Intelligence (XAI) with Morris Sensitivity Analysis (MSA) to enhance both the interpretability and performance of machine learning models in AHF detection. A dataset consisting of 425 AHF patients and 430 controls was analyzed using eight machine learning models, including XGBoost, Histogram-based Gradient Boosting (histGB), Explainable Boosting Machine (EBM), and Random Forest. Model performance was evaluated through metrics such as AUC, accuracy, precision, recall, and Brier score. Hyperparameters were optimized via Bayesian optimization. Feature importance was assessed using MSA to identify variables with the highest predictive influence. The histGB model achieved the highest performance with an AUC of 87.93%. Both MSA and EBM consistently identified PDW, RDW-CV, NEU, NEU/LY ratio, age, and WBC as top predictive features across multiple models. These hematological markers demonstrated strong potential for early diagnosis and risk stratification in AHF patients. This study presents a clinically relevant, interpretable, and cost-effective diagnostic strategy that combines XAI with MSA for AHF prediction. The framework enhances clinical trust and provides a pathway toward personalized treatment by identifying accessible hematological biomarkers. The integration of explainability into AI models improves their transparency and applicability in real-world clinical settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.